VKTX Stock Recent News

Viking Therapeutics' fourth-quarter earnings miss estimates. The decline in stock price was attributable to a lack of material updates on its pipeline.

The excitement surrounding Viking Therapeutics (VKTX 3.49%) stock has been dying down significantly lately. In six months, the stock has lost more than 40% of its value.

Viking Therapeutics stock plunged late Wednesday on an earnings report that included mostly incremental updates for its weight-loss drugs. The post Viking Therapeutics Plummeted 10% On Its Earnings Report.

Viking Therapeutics, Inc. (NASDAQ:VKTX ) Q4 2024 Earnings Conference Call February 5, 2025 4:30 PM ET Company Participants Stephanie Diaz - IR Manager Brian Lian - CEO and President Greg Zante - CFO Conference Call Participants Ryan Deschner - Raymond James Mike Ulz - Morgan Stanley Asim Rana - Truist Securities Jay Olson - Oppenheimer Annabel Samimy - Stifel Mayank Mamtani - B. Riley Securities Biren Amin - Piper Sandler Hardik Parikh - JPMorgan Andy Hsieh - William Blair Yale Jen - Laidlaw & Company Justin Zelin - BTIG Operator Welcome to the Viking Therapeutics Fourth Quarter and Full Year 2024 Financial Results Conference Call.

Conference call scheduled for 4:30 p.m. ET today Initiation of Phase 3 Studies for Subcutaneous VK2735 for Obesity Planned for 2Q25 Phase 2 VENTURE-Oral Dosing Trial Evaluating VK2735 in Obesity Underway Strong Year-End Cash Position of $903 Million SAN DIEGO , Feb. 5, 2025 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced its financial results for the fourth quarter and year ended December 31, 2024, and provided an update on its clinical pipeline and other corporate developments.

Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?

Market uncertainty can make nervous investors leery of investing in industries that are more speculative in nature, such as pharmaceuticals and biotechnology.

Oral VK2735 is strategically positioned to become a best-in-class oral GLP-1 therapy, with the Phase 2 trial data readout in H2 2025 serving as a critical catalyst. Phase 1 data for VK2735 represents the best efficacy and safety profile ever reported for an oral GLP-1 drug. The oral obesity market is projected to be the fastest-growing segment within the broader weight-loss market, driven by the superior convenience of oral formulations compared to injectable treatments.

Medications known as glucagon-like peptide 1 (GLP-1) receptor agonists are taking over the healthcare industry. While you may not be familiar with the term "GLP-1," I'd wager you'll recognize some of the most popular ones on the market today, including Ozempic, Wegovy, Mounjaro, and Zepbound.

Since VKTX is devoid of marketed drugs, investors will focus on pipeline updates when it reports Q4 results next week.